Dr. Mark E. Minor
Pediatric Pulmonology (Pediatric Pulmonology Physician)
At a glance
- Medical school
- Jc Edwards School of Medicine, Marshall University (2008)
- Years since graduation
- 18
- In the NPI registry since
- 2012
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2008Medical school: Jc Edwards School of Medicine, Marshall University
- 2012Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pediatric Pulmonology Physician primary
OH license 35.126257
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Dayton Childrens Hospital Dayton, OH
Medical groups
- Dayton Childrens Specialty Physicians Inc (97 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Payments from drug and device companies
In 2025, 1 companies reported 1 payments worth $44.18 in total to this clinician.
| Viatris Specialty LLC | $44.18 |
|---|
| Education | $44.18 |
|---|
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Viatris Specialty LLC Nov 14, 2025 | Education | $44.18 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $114,761 in research payments for these studies, mostly to the institutions running them.
- A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.